BiotechTube

Neomycin + Placebo + Rifaximin

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Constipation-predominant Irritable Bowel Syndrome

Conditions

Constipation-predominant Irritable Bowel Syndrome

Trial Timeline

Aug 1, 2009 → Jun 1, 2013

NCT ID
NCT00945334

About Neomycin + Placebo + Rifaximin

Neomycin + Placebo + Rifaximin is a pre-clinical stage product being developed by Bausch Health for Constipation-predominant Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00945334. Target conditions include Constipation-predominant Irritable Bowel Syndrome.

Hype Score Breakdown

Clinical
5
Activity
2
Company
5
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00945334Pre-clinicalCompleted

Competing Products

1 competing product in Constipation-predominant Irritable Bowel Syndrome

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
52

Other Products from Bausch Health

nabiloneApproved
80
High dose budesonide rectal foam + Low dose budesonide rectal foam + Matching placebo rectal foamApproved
80
benzoyl peroxide wash + Tretinoin gelApproved
80
Adapalene Gel + Tretinoin GelApproved
80
Omeprazole/sodium bicarbonateApproved
80